Halozyme Therapeutics Q2 Revenue Declines

TL;DR

**HALO Q2 royalties down YoY, watch for impact on guidance.**

AI Summary

Halozyme Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported royalty revenues of $142.4 million for the second quarter of 2024, a decrease from $150.1 million in the same period of 2023. For the first six months of 2024, royalty revenues were $284.3 million, down from $296.7 million in the first half of 2023.

Why It Matters

The decrease in royalty revenue could impact investor confidence and future growth projections for Halozyme Therapeutics.

Risk Assessment

Risk Level: medium — The filing indicates a decrease in royalty revenues, which could signal potential challenges in the company's core business.

Key Numbers

• $142.4M — Q2 2024 Royalty Revenue (Compared to $150.1M in Q2 2023)
• $284.3M — First Six Months 2024 Royalty Revenue (Compared to $296.7M in the first six months of 2023)

Key Players & Entities

• Halozyme Therapeutics, Inc. (company) — Filer
• 20240630 (date) — Reporting period end date
• $142.4 million (dollar_amount) — Q2 2024 royalty revenue
• $150.1 million (dollar_amount) — Q2 2023 royalty revenue
• $284.3 million (dollar_amount) — First six months of 2024 royalty revenue
• $296.7 million (dollar_amount) — First six months of 2023 royalty revenue

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market

Filing Documents

• halo-20240630.htm (10-Q) — 1374KB
• ex101formofrestrictedunita.htm (EX-10.1) — 69KB
• ex31110qq22024.htm (EX-31.1) — 13KB
• ex31210qq22024.htm (EX-31.2) — 13KB
• ex3210qq22024.htm (EX-32) — 14KB
• halo-20240630_g1.jpg (GRAPHIC) — 15KB
• halo-20240630_g2.jpg (GRAPHIC) — 144KB
• halo-20240630_g3.jpg (GRAPHIC) — 75KB
• 0001159036-24-000044.txt ( ) — 8618KB
• halo-20240630.xsd (EX-101.SCH) — 47KB
• halo-20240630_cal.xml (EX-101.CAL) — 80KB
• halo-20240630_def.xml (EX-101.DEF) — 258KB
• halo-20240630_lab.xml (EX-101.LAB) — 660KB
• halo-20240630_pre.xml (EX-101.PRE) — 460KB
• halo-20240630_htm.xml (XML) — 1265KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) - June 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income (Unaudited) - Three and Six Months Ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three and Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows (Unaudited) - Six Months Ended June 30, 2024 and 2023 6 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - Three and Six Months Ended June 30, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 54

Controls and Procedures

Item 4. Controls and Procedures 54

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 55

Risk Factors

Item 1A. Risk Factors 55

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55

Other Information

Item 5. Other Information 55

Exhibits

Item 6. Exhibits 56

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except per share amounts) June 30, 2024 December 31, 2023 ASSETS Current assets Cash and cash equivalents $ 187,864 $ 118,370 Marketable securities, available-for-sale 341,166 217,630 Accounts receivable, net and contract assets 214,524 234,210 Inventories, net 159,312 127,601 Prepaid expenses and other current assets 84,931 48,613 Total current assets 987,797 746,424 Property and equipment, net 75,000 74,944 Prepaid expenses and other assets 52,481 17,816 Goodwill 416,821 416,821 Intangible assets, net 437,354 472,879 Deferred tax assets, net — 4,386 Total assets $ 1,969,453 $ 1,733,270 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 15,430 $ 11,816 Accrued expenses 117,930 100,678 Total current liabilities 133,360 112,494 Long-term debt, net 1,502,515 1,499,248 Other long-term liabilities 30,507 37,720 Deferred tax liabilities, net 13,647 — Total liabilities 1,680,029 1,649,462 Commitments and contingencies (Note 11) Stockholders' equity Preferred stock - $ 0.001 par value; 20,000 shares authorized; no shares issued and outstanding — — Common stock - $ 0.001 par value; 300,000 shares authorized; 126,535 and 126,770 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 127 127 Additional paid-in capital 30,747 2,409 Accumulated other comprehensive loss ( 2,068 ) ( 9,278 ) Retained earnings 260,618 90,550 Total stockholders' equity 289,424 83,808 Total liabilities and stockholders' equity $ 1,969,453 $ 1,733,270 See accompanying notes to condensed consolidated financial statements. 3 HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenues Royalties $ 124,918 $ 111,740 $ 245,511

View Full Filing

View this 10-Q filing on SEC EDGAR